{
  "abstract": "Objectives: We aimed to estimate the prevalence of iMCD in Spain by applying the current international consensus criteria.\n\nMethods: This was an observational, multicenter, cross-sectional study that was conducted in 20 Spanish hospitals. The diagnosis of iMCD and the histological subtype were confirmed by a centralized scientific committee by applying the international consensus criteria. The local clinical, laboratory, and pathology reports were reviewed.\n\nResults: Between February 2023 and April 2024, 30 patients with a documented diagnosis of iMCD were included in the study. The estimated prevalence of iMCD was 0·61 cases per 100,000 inhabitants (95% CI, 0·39–0·83); 23 subjects (76·7%) were classified as iMCD-NOS, and 7 (23·3%) were classified as iMCD-TAFRO. Twenty-two patients (73·3%) had received therapy for iMCD prior to their inclusion in the study. There are currently 21 patients (70%) on treatment, the most common being the use of siltuximab (19 patients; 90·4%). Complete response, partial response, and stable disease were reported in 11 (36·7%), 8 (26·7%), and 9 (30%) patients, respectively, with current treatment.\n\nConclusion: The prevalence of clinical cases of iMCD in Spain comparable to that reported in the literature. Siltuximab is currently the most commonly used therapy. Most patients under treatment showed a favorable clinical response.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hematology, Institut Català d’Oncologia. Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona",
    "Department of Anatomic Pathology, Valdecilla/IDIVAL, Universidad de Cantabria",
    "Department of Internal Medicine, Hospital Universitario Ramón y Cajal",
    "Department Hematology and Hemotherapy, Hospital Regional Universitario de Málaga",
    "Department of Internal Medicine, Hospital Universitario Puerta de Hierro Majadahonda",
    "Department of Hematology, Institut Català D’Oncologia Hospitalet, IDIBELL, Universitat de Barcelona",
    "Department of Hematology, Son Espases University Hospital",
    "Department Haematology, Hospital 12 de Octubre",
    "Department Hematology, Hospital Universitario de Salamanca-IBSAL, CIC- IBMCC (USAL-CSIC), CIBERONC",
    "Department Hematology, University Hospital Miguel Servet",
    "Internal Medicine Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL)",
    "Department of Hematology and Hemotherapy, San Cecilio University Clinical Hospital",
    "Department of Hematology, Hospital Arnau de Vilanova-Lliria",
    "Department of Hematology, Hospital Universitario Donostia",
    "Department of Hematology, Hospital Universitario Central de Asturias",
    "Department of Hematology, Hospital Universitario Virgen del Rocío",
    "Department of Hematology, Hospital Arnau de Vilanova",
    "Systemic Autoinmmune Diseases Unit, Internal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS",
    "Faculty of Medicine and Health Sciences, Universidad de Alcalá (UAH)"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 18,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Jose-Tomas Navarro"
    },
    {
      "affs": [
        1
      ],
      "name": "Santiago Montes-Moreno"
    },
    {
      "affs": [
        2
      ],
      "name": "Grisell Starita Fajardo"
    },
    {
      "affs": [
        3
      ],
      "name": "Manuel Espeso de Haro"
    },
    {
      "affs": [
        4
      ],
      "name": "Pedro Durán-del-Campo"
    },
    {
      "affs": [
        5
      ],
      "name": "Eva Gonzalez-Barca"
    },
    {
      "affs": [
        6
      ],
      "name": "Antonio Gutiérrez"
    },
    {
      "affs": [
        7
      ],
      "name": "Ana Jiménez-Ubieto"
    },
    {
      "affs": [
        8
      ],
      "name": "Alejandro Martín García-Sancho"
    },
    {
      "affs": [
        9
      ],
      "name": "Araceli Rubio-Martínez"
    },
    {
      "affs": [
        10
      ],
      "name": "Rosario Sánchez-Martínez"
    },
    {
      "affs": [
        11
      ],
      "name": "Paloma García-Martín"
    },
    {
      "affs": [
        12
      ],
      "name": "Pablo Lorente-Alegre"
    },
    {
      "affs": [
        13
      ],
      "name": "Iñigo Olazabal Eizaguirre"
    },
    {
      "affs": [
        14
      ],
      "name": "Angel Ramirez Payer"
    },
    {
      "affs": [
        15
      ],
      "name": "Guillermo Rodriguez"
    },
    {
      "affs": [
        16
      ],
      "name": "Antonio García-Guiñon"
    },
    {
      "affs": [
        17,
        18
      ],
      "name": "Andrés González-García"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/etagv1rrx1zsc.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1963499",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724649/?tool=EBI",
  "id": "etagv1rrx1zsc",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1963499/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2745|IgG4-Related and Inflammatory Diseases"
    ]
  ],
  "openalex": "W7222929850",
  "pdf_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1963499/pdf",
  "pmcid": "PMC13724649",
  "pmid": "42973648",
  "published": "2026-10-19",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/etagv1rrx1zsc.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1963499",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1963499/full"
    },
    {
      "first_seen": "2026-11-03T15:20:51Z",
      "native_id": "PMC:PMC13724649",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13724649"
    },
    {
      "first_seen": "2026-11-04T12:23:11Z",
      "native_id": "PMC13724649",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fonc.2026.1963499"
    },
    {
      "first_seen": "2026-11-04T15:20:48Z",
      "native_id": "MED:42973648",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42973648"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "Characteristics of idiopathic multicentric Castleman disease in Spain: results of the registry-based ARCANA multicenter study",
  "title_text": "Characteristics of idiopathic multicentric Castleman disease in Spain: results of the registry-based ARCANA multicenter study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T12:21:04Z",
  "url": "https://research.draconitic.com/paper/etagv1rrx1zsc",
  "venue": "Frontiers in Oncology",
  "versions": []
}